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Abstract
Background: We aimed to describe the safety and efficacy of insulin glargine in Chinese paediatric patients with
type 1 diabetes mellitus (T1DM). Neutral protamine Hagedorn (NPH) insulin was the reference therapy.
Methods: This open-label, randomised, Phase III study was conducted at 10 sites in China. Children aged ≥6 to
<18 years with T1DM were randomised (2:1) to insulin glargine or NPH insulin asbasal insulinfor a 24-week
treatment period. For all patients, insulin aspart was given as bolus insulin. The primary endpoint was absolute
change in glycated haemoglobin(HbA1c) from baseline to Week 24. Secondary endpoints included the percentage
of patients reaching HbA1c <7.5% (<58.5 mmol/mol), and safety. The study was registered at clinicaltrials.gov
(NCT01223131).
Results: In total,196 patients were screened, and 162 were randomised (107 and 55 patients were randomised to
insulin glargine and NPH insulin, respectively). The mean ± SD of absolute change in HbA1c was–0.25 ± 1.68% (–2.69 ±
18.32 mmol/mol) in the insulin glargine group and –0.54 ± 1.67% (–5.55 ± 20.32 mmol/mol) in the NPH insulin group.
At Week 24, 18.7 and 21.6% of patients in the insulin glargine and NPH insulin groups achieved HbA1c <7.5% (<58.
5 mmol/mol). Both treatments were generally well tolerated. A numerically lower rate of symptomatic hypoglycaemia
per patient year was observed for insulin glargine versus NPH insulin (24.3 ± 45.8 versus32.3 ± 43.2); severe
hypoglycaemia was rare (<2%).
Conclusions: Initiation of insulin glargine can aid Chinese paediatric patients with T1DM to safely reduce their HbA1c
levels.
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Background
The prevalence of type 1 diabetes mellitus (T1DM)
among paediatric populations (aged <18 years) has been in-
creasing globally over the last decade [1, 2]. Good blood
glucose control can be achieved using multiple daily injec-
tions of basal and bolus insulin [3]. Several long-acting in-
sulin analogues have been developed to provide a slow-
release insulin that attempts to mimic the physiological
action of natural basal insulinin healthy individuals [4].
Compared with intermediate-acting neutral protamine
Hagedorn (NPH) insulin, long-acting insulin analogues
have a relatively longer duration of action and a less pro-
nounced peak insulin concentration [4].
Insulin glargine is an insulin analogue that was engi-
neered to have a lower solubility at physiological pH than
natural insulin, thereby facilitating a prolonged absorption
following subcutaneous injection and providing asteady
24-h basal insulin supply [5, 6]. A meta-analysis of stud-
ies that were predominantly conducted in Europe and
North America concluded that insulin glargine and NPH
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insulin have comparable efficacy in terms of HbA1c levels
as well as broadly comparable safety profiles in paediatric
patients with T1DM [7]. Nonetheless, insulin glargine is a
once-daily injection, whereas NPH insulin dosing varies
and can require multiple daily injections. Using once-daily
insulin glargine to attain glycaemic control can thus re-
duce the total number of daily injections, which, in turn,
can reduce lipodystrophy, injection-site pain and bruising,
which is associated with multiple daily injections,particu-
larly in younger children [8, 9]. Furthermore, insulin
glargine has been associated with better control of fast-
ing blood glucose (FBG) levels, lower incidence of hypo-
glycaemia,and nocturnal free insulin levels [10–13].
Insulin glargine is approved in Europe and the USA
for use in both adults and paediatric patients with
T1DM [5, 6]. However, in China, insulin glargine is ap-
proved for use only in adults with T1DM. To date,
there have been relatively few reports of insulin glargi-
nein paediatric patients with T1DM [7, 14, 15], and
prior to the present study, there have been no reports
regarding the efficacy and safety of insulin glargine in
Chinese children with T1DM. Therefore, the purpose
of the present study was to describe the safety and effi-
cacy of once-daily insulin glargine over a period of
24 weeks in Chinese paediatric patients with T1DM.
Methods
Patients and study design
This was a 24-week,Phase III, randomised, open-label,
parallel-group study. Paediatric patients aged ≥6 to <18 years
with T1DM (duration ≥1 year) were eligible for enrolment.
Other key exclusion criteria are described in the Additional
file 1 (Methods). The study protocols and a subsequent
protocol amendment were approved locally by independent
ethics committees, and written informed consent was ob-
tained from the parent or legal guardian of each patient.
The study was performed in accordance with the Declar-
ation of Helsinki, and registered at clinicaltrials.gov
(NCT01223131).
Patients were centrally randomised in a block size of
six and in a 2:1 ratio to receive insulin glargine (Lantus,
Sanofi, Paris, France) by subcutaneous injection once
daily at bedtime (20:00–22:00), or NPH insulin (Novolin
N, Novo Nordisk, Copenhagen, Denmark) by subcutane-
ous injection either once daily at bedtime or twice daily:
once before breakfast and once at bedtime. Investigators
were allowed to select which of these two methods was
more appropriate for their patients. Randomisation was
conducted using an interactive voice response system and
patients were stratified according to screening age (<12 years,
≥12 years) and screening HbA1c (<9% [<74.9 mmol/mol],
≥9% [≥74.9 mmol/mol]). A 2:1 randomisation ratio allowing
a greater number of patients exposure to insulin glargine
was used in order to help improve the precision of the safety
assessment of insulin glargine in the patient population.
Insulin aspart (NovoRapid, Novo Nordisk) solution for
injection was provided as the sole source of bolus insulin.
Insulin dose was adjusted individually to maintain the de-
sired degree of metabolic control without hypoglycaemia
(Additional file 1).
The 24-week treatment period was preceded by a
screening period of ≤2 weeks plus a 1-week run-in period,
and followed by a 1-week post-treatment follow-up. Clinic
consultations occurred at screening/run-in (Week –3 to –
2 and Week –1), randomisation (Week 0), Weeks 1, 2, 4,
6, 8, 10, 12, 16, 20, 24 (end of treatment) and Week 25
(follow-up).
HbA1c was measured at screening, Week 0, Week 12, and
Week 24 at a central laboratory using a high-performance li-
quid chromatography system (Variant™ II Hemoglobin
Testing System, Bio-Rad, Hercules, CA, USA). The HbA1c
reference values of the system were such that a HbA1c of
<6% (<42.1 mmol/mol) was considered to be a non-diabetic
level, a HbA1c of <7%(<53.0 mmol/mol) the target HbA1c
level and a HbA1c of >8% (>63.9 mmol/mol) the need for
action to lower HbA1c. The accuracy ranges (coefficients of
variation) of the system were 0.59–0.90% within-run and
0.46–0.64% between-run. All blood glucose assessments,
including FBG, nocturnal blood glucose, and self-monitored
blood glucose (SMBG) profiles were self-monitored and col-
lected for data analyses. FBG was measured in the morning
on 6 consecutive days immediately preceding each clinic
visit and on the day of the visit before insulin administra-
tion. Subjects established a four-point blood glucose profile
(before each of the three main meals, and at bedtime) at
least twice a week and as needed for glycaemic monitoring,
and an eight-point glucose profile (at 3:00 a.m.; immediately
before and 2 h after breakfast, lunch and dinner, and at bed-
time) once a week. If the blood glucose measurement 2 h
after dinner coincided with the bedtime measurement,
reducing the eight-point SMBG to seven values was permit-
ted. Plasma samples for pharmacokinetic analysis were ob-
tained in the morning at Weeks 1, 2 and 4 from subjects in
the insulin glargine group at selected sites, and samples
were analysed at a central laboratory for concentrations of
insulin glargine and its metabolites M1 and M2. Positivity
for anti-glargine antibody (AGA) and anti-insulin antibody
(AIA) was determined in a semi-quantitative manner by
measurement of antibody binding to the iodinated insulin
tracers 125I- insulin glargine and 125I-human insulin.
Enrolment
Initially, it was planned to enrol 366 patients, with 244 pa-
tients randomised to insulin glargine and 122 to NPH in-
sulin. However, recruitment of patients for the study was
difficult due to the limited number of China Food and
Drug Administration (CFDA)-accredited endocrinology
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sites and relatively low incidence of T1DM in China. Two
years after enrolment of the first patient, a total of 108 pa-
tients were screened and 93 randomised, which consti-
tuted only 25% of the original enrolment target. A
decision to amend the study protocol with a reduced
enrolment target was made primarily to ensure the quality
of the study data; 2 years into the study, the total
recruitment period was estimated at >5 years, and over
this timescale it would have been challenging to control
the influence of factors such as changes in the standard of
care on the study data. Therefore, the study protocol was
amended to reduce the planned number of enrolled pa-
tients to 150, with 100 patients randomised to insulin glar-
gine and 50 to NPH insulin (Additional file 1).
Between February 2011 and March 2014, 196 patients
were screened at 10 CFDA-accredited endocrinology
centres in China. Of the 196, 34 patients were excluded
and 162 enrolled (Fig. 1).
Study outcomes
The primary endpoint of the study was absolute change
in HbA1c from baseline to Week 24, and key secondary
treatment efficacy endpoints were the percentage of
patients reaching the International Society of Pediatric
and Adolescent Diabetes (ISPAD)-recommended HbA1c
target of <7.5% (<58.5 mmol/mol), and change in FBG,
nocturnal blood glucose, 24-h blood glucose profile
based on an eight-point SMBG profile measured using
Performa blood glucose meters (Roche Diagnostics
Gmbh, USA), and daily total insulin and basal insulin
dose, from baseline to Week 24. SMBG profiles were
used in posthoc analyses to assess glucose variability and
the risk of hypoglycaemia and hyperglycaemia, which
were defined by the low blood glucose risk index (LBGI)
and the high blood glucose risk index (HBGI), respecti-
vely,and were calculated using previously described
methods [16]. The insulin glargine pharmacokinetic pro-
file was assessedat selected sites to rule out any tendency
for accumulationin paediatric patients after repeated
dosing, and safety parameters included AGA and AIA
development, the incidence of hypoglycaemia, and ad-
verse event monitoring. The classification of
hypoglycaemia is described in the Additional file 1.
A posthoc analysis was performed to evaluate the per-
centage of patients with HbA1c 7.5–9% (58.5–74.9 mmol/
mol) and > 9% (>74.9 mmol/mol) at Week 24, which indi-
cates patients with acceptable but sub-optimal glycaemic
control and high-risk patients, respectively, as defined by
the Chinese Diabetes Society guidelines [17]. A posthoc
analysis of the daily dose of basal and bolus insulin was
also performed.
Statistical methods
Based on the smaller-than-planned sample size, the proto-
col amendment made provision for descriptive statistics of
the study endpoints, only. A statistical assessment of effi-
cacy (not described in the protocol) was conducted as a
sub-analysis. For this assessment, a modified intent-to-
Fig. 1 Patient flow diagram.*Patients could be excluded for more than one reason.†Serum creatinine > 177 μmol/l (2.0 mg/dl); serum alanine amino
transferase or aspartate amino transferase > 3 times upper limit of normal for the patient’s age and gender; haemoglobin <10 g/dl (100 g/l) and/or
neutrophils < 1500/mm3 (1.5 × 109/l) and/or platelets < 100,000/mm3 (100 × 109/l).cThreepatients had no post-baseline HbA1c assessment and were
not included in the HbA1c analysis
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treat (mITT) population was used for statistical compari-
sons between treatment groups. The mITT was defined as
all randomised patients who received at least one dose of
study medication and for whom a baseline and at least one
post-baseline assessment for any of the study endpoints
were available. For patients with missing data at Week 24,
the last observation carried forward (LOCF) approach was
taken.
Differences between treatment groups for mean change
in HbA1c, FBG, and daily total or basal insulin dose from
baseline to Week 24 were assessed using an analysis of
covariance (ANCOVA) model with treatment group, ran-
domisation strata of screening age (<12 years, ≥12 years),
randomisation strata of screening HbA1c (<9% [<74.9 mmol/
mol], ≥9% [≥74.9 mmol/mol]) as fixed effects, and baseline
value as covariate.
Differences between treatment groups in the number
(%) of patients who achieved an HbA1c target of <7.5%
(<58.5 mmol/mol) at Week 24 were assessed using the
Cochran–Mantel–Haenszel method stratified by screening
age strata (<12 years, ≥12 years) and screening HbA1c
strata (<9% [<74.9 mmol/mol], ≥9% [≥74.9 mmol/mol]).
For the assessment of safety, data were described for a
safety population, which was defined as all randomised pa-
tients who received at least one dose of study medication.
All continuous data were summarised using the number
of observations available (n) and mean ± SD and median
(quartile 1, quartile 3). Categorical data were summarised
using the count and percentage. Further details are
described in the Additional file 1.
Results
Patients
A total of 162 patients were randomised to receive insulin
glargine (n = 107) or NPH insulin (n = 55). One patient
randomised to NPH insulin withdrew consent; thus, the
final mITT and safety populations for the insulin glargine
and NPH insulin groups comprised 107 and 54 patients,
respectively. Five patients who received at least one dose
of study medication were discontinued from the study
prematurely; one patient in the insulin glargine group and
three patients in the NPH insulin group were discontin-
ued due to poor compliance to the protocol; one patient
in the NPH insulin group was discontinued due to a se-
vere adverse event (SAE) of increased blood glucose.
Therefore, a total of three patients in the NPH insulin
group had no post-baseline HbA1c assessement and were
not included in the statistical analysis for HbA1c.
Demographics and baseline characteristics were gen-
erally comparable between the two treatment groups
(Additional file 2: Table S1). Compared with patients in
the NPH insulin treatment group, a greater proportion
of patients in the insulin glargine group were male
(41.4% versus 35.2%). Patients in the insulin glargine
group had a numerically lower mean baseline HbA1c
level than those in the NPH insulin group (8.87 ± 1.21%
[73.48 ± 13.27 mmol/mol] versus 9.12 ± 1.29% [76.16 ±
14.04 mmol/mol]). One patient in the NPH insulin treat-
ment group had diabetic nephropathy (microalbuminuria).
Efficacy
Primary endpoint
The mean absolute change in HbA1c level from base-
line to Week 24 was–0.25 ± 1.68%(–2.69 ± 18.32 mmol/
mol) for patients who received insulin glargine, and –
0.54 ± 1.67% (–5.55 ± 20.32 mmol/mol) for those who
received NPH insulin (Table 1). The median changes in
HbA1c in the treatment groups were numerically similar.
At Week 24, the mean HbA1c levels of the insulin glar-
gine and NPH insulin treatment groups were 8.63 ± 1.54%
(70.79 ± 16.81 mmol/mol) and 8.59 ± 1.79% (70.43 ±
19.60 mmol/mol), respectively.
The percentage of patients reaching HbA1c <7.5%
(<58.5 mmol/mol) at Week 24 was 18.7% in the insulin
glargine group and 21.6%in the NPH insulin group, re-
spectively. At all study time points and in both treatment
groups,the mean HbA1c was numerically lower than that
at baseline (Fig. 2a).
Secondary endpoints
From baseline to Week 24, the mean FBG decreased in
patients who received insulin glargine from 10.38 ±
3.38 mmol/l to 9.61 ± 2.63 mmol/l and increased in pa-
tients who received NPH insulin from 10.20 ± 2.75 mmol/
l to 11.29 ± 3.35 mmol/l (Table 1). There was considerable
difference in change in FBG between the insulin glargine
and NPH treatment groups (–0.76 ± 3.56 mmol/l versus
1.07 ± 3.64 mmol/l;95% CI: –2.62 to –0.76) and FBG was
better controlled with insulin glargine than with NPH in-
sulin at all study time points (see Fig. 2b).
The mean changes in nocturnal blood glucose and eight-
point SMBG levels from baseline to Week 24 in the insulin
glargine and NPH insulin groups were similar (Table 1).
LBGI and HBGI that were calculated using the SMBG pro-
file data as part of the posthoc analysis were also similar for
both treatment groups (Additional file 3: Table S2). Further-
more, a trend for greater stability of mean nocturnal blood
glucose and eight-point SMBG over the study period was
observed in patients who received insulin glargine versus
NPH insulin (Fig. 2c, d).
At baseline, the mean daily total and daily basal insulin
doses for the insulin glargine and NPH insulin groups were
numerically similar (0.84 ± 0.23units/kg/day versus 0.87 ±
0.29units/kg/day for total insulin and 0.29 ± 0.09units/kg/
day versus 0.31 ± 0.13units/kg/day for basal insulin,
respectively). Compared with baseline, at Week 24 the
NPH insulin group had a greater numerical increase in
both the mean daily total and basal insulin doses than the
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Table 1 Summary of blood glucose control endpoints in the modified intention-to-treat analysis population with last observation
carried forward for missing observations at Week 24
Insulin glargine NPH insulin
(n = 107) (n = 54)
n Mean ± SD Median n Mean ± SD Median
(Q1, Q3) (Q1, Q3)
HbA1c, % (mmol/mol)a
Baseline 107 8.87 ± 1.21 8.90 (7.90, 9.70) 54 9.12 ± 1.29 8.90 (7.90, 10.20)
(73.47 ± 13.27) (73.77 [62.84, 81.97]) (76.16 ± 14.04) (73.77 [63.11, 87.98])
Week 24 103 8.57 ± 1.47 (8.40 [7.70, 9.20]) 50 8.60 ± 1.81 8.30 (7.60, 9.40)
(70.13 ± 16.06) (68.31 [61.20,76.50]) (70.49 ± 19.79) (67.21 [59.56, 78.96])
Changeb 103 −0.31 ± 1.56 −0.50 (–1.20, 0.60) 50 −0.57 ± 1.68 −0.40 (–1.20, 0.40)
(–3.30 ± 19.52) (–3.28 [–14.75, 7.65]) (–5.57 ± 21.51) (–3.83 [-15.30, 5.19])
Week 24 (LOCF)c 107 8.63 ± 1.54 8.40 (7.70, 9.20) 51 8.59 ± 1.79 8.30 (7.60, 9.40)
(70.79 ± 16.81) (68.31 [61.20, 77.05]) (70.43 ± 19.60) (67.21 [59.56, 78.69])
Change (LOCF)b 107 −0.25 ± 1.68 −0.50 (–1.20, 0.60) 51 −0.54 ± 1.67 −0.40 (–1.20, 0.40)
(–2.69 ± 18.32) (–5.46 [–13.11, 6.56]) (–5.55 ± 20.32) (–3.28 [–15.30, 4.92])
LS Mean difference 0.16 (0.26)
95% CI −0.36 to 0.68
HbA1c at Week 24, n (%)a
<7.5% (<58.5 mmol/mol)d 107 20 (18.7) – 51 11 (21.6) –
7.5% to 9.0% (58.5–74.9 mmol/mol) 107 56 (52.3) – 51 26 (51.0) –
>9.0% (>74.9 mmol/mol) 107 31 (29.0) – 51 14 (27.5) –
Fasting blood glucose, mmol/Le
Baseline 105 10.38 ± 3.38 10.08 (8.22, 12.24) 52 10.20 ± 2.75 10.59 (8.38, 11.88)
Week 24 96 9.45 ± 2.60 9.17 (7.56, 11.01) 44 10.89 ± 3.19 10.14 (8.51, 12.74)
Changeb 94 −0.85 ± 3.73 −0.05 (–2.95, 1.24) 42 0.54 ± 3.34 0.49 (–1.45, 3.66)
Week 24 (LOCF)c 107 9.61 ± 2.63 9.30 (7.72, 11.59) 54 11.29 ± 3.35 10.81 (8.84, 13.00)
Change (LOCF)b 105 −0.76 ± 3.56 −0.05 (–2.47, 1.23) 52 1.07 ± 3.64 0.71 (–1.45, 3.86)
LS Mean difference −1.69 (0.47)
95% CI −2.62 to –0.76
Nocturnal blood glucose, mmol/Lf
Baseline 88 8.89 ± 4.47 8.00 (5.50, 11.80) 45 9.38 ± 4.81 8.10 (6.00, 12.00)
Week 24 89 9.44 ± 4.88 8.80 (5.60, 11.90) 42 8.88 ± 3.94 8.75 (5.80, 11.20)
Changeb 75 0.42 ± 6.26 0.30 (–3.60, 4.60) 35 −0.14 ± 5.97 1.60 (–3.20, 3.70)
Week 24 (LOCF)c 106 9.44 ± 4.83 8.80 (5.60, 12.20) 54 9.56 ± 4.39 9.05 (6.20, 12.80)
Change (LOCF)b 88 0.59 ± 6.16 0.15 (–3.00, 3.95) 45 0.24 ± 5.80 1.60 (–3.00, 3.70)
LS Mean difference −0.03 (0.88)
95% CI −1.77 to 1.70
Eight-point SMBG, mmol/L
Baseline 104 10.01 ± 3.30 9.46 (7.54, 11.72) 53 10.00 ± 2.98 9.66 (7.51, 11.83)
Week 24 94 10.00 ± 3.10 9.46 (7.75, 11.85) 45 9.42 ± 2.74 8.86 (7.91, 10.81)
Changeb 92 0.28 ± 4.39 0.28 (–2.30, 2.84) 44 −0.58 ± 3.99 −0.59 (–2.96, 1.99)
Week 24 (LOCF)c 107 9.94 ± 3.00 9.49 (7.75, 11.85) 54 9.75 ± 2.83 9.02 (7.98, 11.25)
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insulin glargine group (0.07 ± 0.16units/kg/day versus 0.19
± 0.26 units/kg/day for total insulin and 0.02 ± 0.07units/
kg/day versus0.11 ± 0.14units/kg/day for basal insulin,
respectively; ANCOVA, Table 2). Consequently, at
Week 24,the insulin glargine group had lower total and
basal insulin doses than the NPH group (0.91 ± 0.25 units/
kg/day versus 1.06 ± 0.32units/kg/day for total insulin, and
0.31 ± 0.09units/kg/day versus 0.43 ± 0.16units/kg/day for
basal insulin, respectively). The mean changes in daily bolus
insulin from baseline to Week 24 were numerically similar
in the treatment groups (0.05 ± 0.12units/kg/day versus0.06
± 0.17units/kg/day for the insulin glargine and NPH insulin
groups, respectively).
Safety
Overall, both study drugs were well tolerated and only one
patient discontinued treatment due to an SAE (increased
blood glucosein the NPH insulin group; Table 3). A lower
total incidence of drug-related treatment-emergent adverse
events (TEAEs) was reported for patients in the insulin
glargine group, compared with the NPH insulin group;the
most common drug-related TEAEs were hypoglycaemia
Table 1 Summary of blood glucose control endpoints in the modified intention-to-treat analysis population with last observation
carried forward for missing observations at Week 24 (Continued)
Change (LOCF)b 104 0.01 ± 4.30 0.01 (–2.58, 2.44) 53 −0.28 ± 3.92 −0.21 (–2.87, 2.69)
LS Mean difference 0.31 (0.50)
95% CI −0.68 to 1.30
aThe analysis excluded measurements obtained >14 days after treatment cessation
bChange from Baseline to Week 24
cFor Week 24 (LOCF), the analysis included measurements obtained ≤14 days after the last dose of study medication
dAnalysis of number (%) of patients with HbA1c <7.5% (<58.5 mmol/mol) at Week 24 was not statistically significant; P = 0.6594
eThe analysis excluded measurements obtained >1 day after treatment cessation
fNocturnal blood glucose was measured at 03:00 a.m.
LS least square, Q1 quartile 1, Q3 quartile 3 SD, standard deviation, SMBG self-monitored blood glucose
Fig. 2 Variation in study variables over the 24-week study window for the mITT population. a Mean HbA1c (%). The analysis excluded measurements
obtained >14 days after treatment cessation and for Week 24 (LOCF), the analysis included measurements obtained ≤14 days after the last dose of
study medication. b Mean fasting blood glucose (mmol/l). The analysis excluded measurements obtained >1 day after treatment cessation. c Mean
nocturnal blood glucose (mmol/l). The analysis excluded measurements obtained >1 day after treatment cessation. d Mean eight-point
SMBG (mmol/l). Error bars represent the standard deviation. LOCF, last observation carried forward; SMBG, self-measured blood glucose
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(33.6% versus 40.7%) and weight gain (0.9% versus 1.9%). A
total of 10 serious TEAEs were reported: four events in
three patients in the insulin glargine group and six events
in six patients in the NPH insulin group. Diabetic ketoaci-
dosis was the most commonly reported serious TEAE.
From screening to Week 24, the proportion of AGA-
and AIA-positive patients in the insulin glargine group
decreased by 4.1% for both AGA and AIA, respectively
(Table 3). In the NPH insulin group, the proportion of
AIA-positive patients increased by 6.9%, while the pro-
portion of AGA-positive patients did not change.
The frequency and event rates of hypoglycaemia are sum-
marised in Table 4. More than 90% of patients in both treatment
groups experienced ≥1 episode of hypoglycaemia. However, the
insulin glargine group had a numerically lower rate of any
hypoglycaemic events per patient year than the NPH insulin
group (68.6±69.4 versus 84.6±79.3). The proportion of patients
who experienced ≥1 symptomatic hypoglycaemic event and the
rate of symptomatic hypoglycaemic events per patient year were
also numerically lower in the insulin glargine group than
in the NPH insulin group. Only a small proportion of all
patients experienced severe symptomatic hypoglycaemia
(<2%). Nocturnal symptomatic hypoglycaemia was less
common in patients who received insulin glargine (37.4%)
than in those who received NPH insulin (46.3%).
No accumulation of insulin glargine or insulin glargine
metabolites M1 orM2 occurred after repeated dosing.
Discussion
Insulin glargine, a long-acting insulin analogue, is avail-
able as a treatment option for paediatric patients with
T1DM in Europe and the USA. However,as there are
Table 2 Daily insulin doses for the modified intention-to-treat analysis population with last observation carried forward for missing
observations at Week 24
Insulin glargine NPH insulin
n Mean ± SD Median n Mean ± SD Median
(Q1, Q3) (Q1, Q3)
Mean daily total insulin, units/kg/day ± SDa
Baseline 107 0.84 ± 0.23 0.82 (0.67, 1.00) 53 0.87 ± 0.29 0.82 (0.70, 1.05)
Week 24 106 0.91 ± 0.25 0.91 (0.73, 1.04) 50 1.08 ± 0.32 1.11 (0.86, 1.28)
Changeb 106 0.08 ± 0.16 0.07 (–0.02, 0.17) 50 0.19 ± 0.26 0.18 (–0.00, 0.35)
Week 24 (LOCF) 107 0.91 ± 0.25 0.91 (0.73, 1.04) 53 1.06 ± 0.32 1.06 (0.85, 1.26)
Change (LOCF)b 107 0.07 ± 0.16 0.07 (–0.03, 0.17) 53 0.19 ± 0.26 0.16 (–0.00, 0.35)
LS Mean Difference −0.13 (0.03)
95% CI −0.19 to –0.06
Mean daily basal insulin, units/kg/day ± SDa
Baseline 107 0.29 ± 0.09 0.28 (0.23, 0.34) 53 0.31 ± 0.13 0.32 (0.23, 0.38)
Week 24 106 0.31 ± 0.09 0.29 (0.25, 0.37) 50 0.44 ± 0.16 0.44 (0.34, 0.52)
Changeb 106 0.03 ± 0.07 0.02 (–0.01, 0.06) 50 0.12 ± 0.14 0.11 (0.04, 0.20)
Week 24 (LOCF) 107 0.31 ± 0.09 0.29 (0.25, 0.38) 53 0.43 ± 0.16 0.43 (0.30, 0.50)
Change (LOCF)b 107 0.02 ± 0.07 0.02 (–0.01, 0.06) 53 0.11 ± 0.14 0.11 (0.04, 0.20)
LS Mean Difference −0.01 (0.02)
95% CI −0.13 to –0.06
Mean daily bolus insulin, units/kg/day ± SD
Baseline 107 0.55 ± 0.18 0.53 (0.42, 0.68) 52 0.58 ± 0.23 0.54 (0.40, 0.73)
Week 24 106 0.60 ± 0.19 0.58 (0.48, 0.71) 49 0.64 ± 0.23 0.63 (0.46, 0.81)
Changeb 106 0.05 ± 0.12 0.04 (–0.02, 0.10) 49 0.06 ± 0.17 0.06 (–0.07, 0.18)
Week 24 (LOCF) 107 0.60 ± 0.19 0.57 (0.47, 0.71) 52 0.63 ± 0.23 0.63 (0.45, 0.81)
Change (LOCF)b 107 0.05 ± 0.12 0.04 (–0.03, 0.10) 52 0.06 ± 0.17 0.06 (–0.06, 0.18)
LS Mean Difference −0.02 (0.02)
95% CI −0.06 to 0.03
aCalculated as the weekly average
bChange from baseline to Week 24
LS least square, Q1 quartile 1, Q3 quartile 3, SD standard deviation
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currently no data on the safety and efficacy of insulin
glargine in Chinese children, it is not an approved
treatment in China for T1DM in paediatric patients. To
the authors’ knowledge, this is the first Phase III
study investigating insulin glargine in Chinese paediat-
ric patients with T1DM.
The data in this study show that Chinese paediatric
patients with T1DM can achieve adequate glycaemic con-
trol with a once-daily administration of insulin glargine.
The mean and median absolute changes in HbA1c were –
0.25 ± 1.68%(–2.69 ± 18.32 mmol/mol) and –0.50% (–1.20,
0.60) (–5.46 mmol/mol [–13.11, 6.56]) after the 24-week
treatment period with insulin glargine. The marketed and
widely prescribed intermediate-acting NPH insulin served
as reference treatment, and the mean and median absolute
changes in HbA1c from baseline to Week 24 in the NPH
insulin treatment group were –0.54 ± 1.67% (–5.55 ±
20.32 mmol/mol) and –0.40% (–1.20, 0.40) (–3.28 mmol/
mol [–15.30, 4.92]), respectively.
Furthermore, at Week 24, a HbA1c of <7.5%
(<58.5 mmol/mol) was achieved by 18.7 and 21.6% of
patients in the insulin glargine and NPH insulin groups,
respectively. Interestingly, in addition to the compar-
able effects that were observed on HbA1c, HBGI was
also found to be similar between the treatment groups.
This is consistent with a previous study, which found a
strong correlation between HBGI and glycosylated
haemoglobin levels [18].
Earlier studies involving the treatment of paediatric
patients with T1DM with insulin glargine have reported
reductions in HbA1c between –0.6 and 0.28%, comparable
with the findings in our study [10, 11, 19–21]. A post-hoc
analysis of data from the present study showed that
the majority of patients in the insulin glargine and
NPH insulin treatment groups achieved HbA1c ≤9.0%
(≤74.9 mmol/mol) at Week 24 (71% and 72.6%), and
Table 3 Summary of safety data
Insulin glargine NPH insulin
(n = 107) (n = 54)
Mean duration of study treatment,
days ± SD
167.5 ± 9.6 157.6 ± 38.9
Treatment discontinuation, n (%) 1 (1) 4 (7.3)
Due to TEAEa, n (%) 0 (0) 1 (1.9)b
≥1 treatment-related TEAEa, n (%) 37 (34.6) 24 (44.4)
Hypoglycaemia 36 (33.6) 22 (40.7)
Overweight 1 (0.9%) 1 (1.9)
Dizziness 0 (0) 1 (1.9)
Injection site swelling 0 (0) 1 (1.9)
Hunger 0 (0) 1 (1.9)
Blood glucose increased 0 (0) 1 (1.9)
Serious TEAE,ac n (%) 4 (2.8) 6 (11.1)
Diabetic ketoacidosis 2 (1.9) 3 (5.6)
Mumps 1 (0.9) 0 (0)
Acute pancreatitis 1 (0.9) 0 (0)
Blood glucose increase 0 (0) 1 (1.9)
Hypoglycaemia 0 (0) 1 (1.9)
Respiratory tract infection 0 (0) 1 (1.9)
AGA-positive, n/n (%)
Screening 74/107 (69.2) 43/55 (78.2)
Week 24 69/106 (65.1) 39/50 (78.0)
Shift from negative to positive, n/n (%) 7/32 (21.9) 5/10 (50.0)
Shift from positive to negative, n/n (%)12/74 (16.2) 6/40 (15.0)
AGA titre, mean ± SD
Screening 41.4 ± 90.2 41.3 ± 86.9
Week 24 56.6 ± 150.9 28.8 ± 44.3
AIA-positive, n (%)
Baseline 65/107 (60.7) 38/55 (69.1)
Week 24 60/106 (56.6) 38/50 (76.0)
Shift from negative to positive, n/n (%) 5/41 (12.2) 5/14 (35.7)
Shift from positive to negative, n/n (%)10/65 (15.4) 2/35 (5.7)
AIA titre, mean ± SD
Screening 69.2 ± 177.1 50.1 ± 63.9
Week 24 66.9 ± 169.0 33.7 ± 34.0
aThe TEAEs and serious TEAEs during the on-treatment period were presented
by preferred terms
bBlood glucose increase
cPatients may have experienced more than one adverse event
TEAE treatment emergent adverse event, AGA anti-glargine antibody, AIA
anti-insulin antibody, SD standard deviation
Table 4 Summary of hypoglycaemia frequency and event rates
Insulin glargine NPH insulin
(n = 107) (n = 54)
Any hypoglycaemiaa, n (%) 99 (92.5) 51 (94.4)
Events per patient yearb, mean ± SD 68.6 ± 69.4 84.6 ± 79.3
Asymptomatic hypoglycaemiaa, n (%) 93 (86.9) 47 (87.0)
Events per patient yearb, mean ± SD 44.4 ± 48.7 52.3 ± 65.3
Symptomatic hypoglycaemiaa, n (%) 74 (69.2) 41 (75.9)
Events per patient yearb, mean ± SD 24.3 ± 45.8 32.3 ± 43.2
Severe symptomatic hypoglycaemiaa, n (%) 1 (0.9) 1 (1.9)
Events per patient yearb, mean ± SD 0.02 ± 0.20 0.04 ± 0.31
Nocturnal hypoglycaemiaa, n (%) 83 (77.6) 42 (77.8)
Events per patient yearb, mean ± SD 13.0 ± 15.0 14.2 ± 16.9
Nocturnal symptomatic
hypoglycaemiaa, n (%)
40 (37.4) 25 (46.3)
Events per patient yearb, mean ± SD 3.6 ± 7.3 4.5 ± 7.4
aCalculated as the total number of patients with at least one episode from the
first dose of treatment up to 24 h after the last dose of treatment divided by
the total number of patients in the safety population
bCalculated as the total number of episodes divided by the total duration from
the first dose to ≤24 h after the last dose of study medication (in years)
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therefore achieved acceptable glycaemic control as defined
by the Chinese Diabetes Society guidelines [17]. A study
by Schoberet al.,identical to the present study in length
and insulin type/dosing, also reported comparable
changes in HbA1c from baseline to Week 24 for insulin
glargine and NPH insulin, although, in contrast to the
present study, the changes from baseline were positive for
both types of insulin (0.28 and 0.27%; p = 0.93) [11].
Previous reports in paediatric patients with T1DM
have also reported greater reductions in FBG with insu-
lin glargine versus NPH insulin,despite demonstrating
comparable efficacy in terms of HbA1c [10, 11, 19–21].
The changes in FBG from baseline to Week 24 observed
in this study support these findings. There was a consid-
erable difference in the change in FBG between the
insulin glargine and NPH insulin groups (–0.76 ±
3.56 mmol/l versus 1.07 ± 3.64 mmol/l); mean FBG
decreased in the insulin glargine group (from 10.38 ±
3.38 mmol/l to 9.61 ± 2.63 mmol/l) and increased in the
NPH insulin group (from 10.20 ± 2.75 mmol/l to
11.29 ± 3.35 mmol/l). Interestingly, a relatively large
study (N = 175), which compared insulin glargine plus
insulin lisprowith NPH insulin or lenteinsulin plus in-
sulin lispro, also reported better control of FBG from
baseline to endpoint with insulin glargine compared with
NPH insulin or lente insulin (–3.3 mg/dl versus 1.1 mg/dl),
although this was not statistically significant (p = 0.6962)
[19]. Overall,the results in paediatric patients are broadly
similar to those reported in adults with T1DM, which con-
sistently demonstrate greater reductions in FBG, although
results regarding reductions in HbA1c for insulin glar-
gine versus NPH insulin are conflicting [14].
At the end of the 24-week treatment period, patients
in the insulin glargine group used considerably lower
total and basal insulin doses than the NPH group (0.91
± 0.25units/kg/day versus1.06 ± 0.32units/kg/day for total
insulin, and 0.31 ± 0.09 units/kg/dayversus0.43 ± 0.16units/
kg/day for basal insulin, respectively) to achieve glycaemic
control. Adequate glycaemic control is central to reducing
the long-term complications of diabetes, and it is likely that
a dosing regimen which achieves glycaemic control with
the least amount of total/basal insulin dose per day, will
enable the achievement of greater control with fewer inci-
dences of hypoglycaemia. In the present study, the
insulin glargine group had a numerically lower rate of
any hypoglycaemia per patient year than the NPH
insulin group (68.6 ± 69.4 versus 84.6 ± 79.3). The inci-
dence of hypoglycaemia observed in the present study
is less than that previously reported in studies involv-
ing European children; the previously mentioned study by
Schoberet al.reported a greater proportion of patients
experiencing ≥1 episode of symptomatic hypoglycaemia
(78.9% and 79.3%, versus 69.2% and 75.9% in the present
study) and severe hypoglycaemia (23.0% and 28.6%, versus
0.9% and 1.9% in the present study) with both insulin glar-
gine and NPH insulin [11]. This suggests that insulin glar-
gine and NPH insulin may be associated with a lower
frequency of symptomatic and severe hypoglycaemia in
Chinese paediatric patients with T1DM compared with
their European counterparts. In accordance with this hy-
pothesis, LBGI, a known predictor of severe hypoglycaemia,
was similarly low in patients treated with insulin glargine
and NPH insulin in this study. Although data on patients’
lifestyles were not collected in the present study, differences
in factors such as bedtime and diet may have contributed
to this apparent difference in hypoglycaemia. However,
given that the changes in HbA1c from baseline to Week 24
in the study by Schoberet al.[11] were different to those in
the present study, and that insulin dose was not presented,
this comparison of hypoglycaemia between both studies is
limited. In addition, nocturnal hypoglycaemia was experi-
enced by a smaller proportion (<30%) of patients in the
study by Schoberet al. compared with the present study
(~78%) [11].
Overall, both insulin glargine and NPH insulin were
well tolerated, and no new safety signals were ob-
served in Chinese paediatric patients with T1DM
when compared with the safety profiles reported
by large trials in European and American paediatric
T1DM populations [10, 11, 19].
Taken together, data from this study supports the hy-
pothesis of previous studies: insulin glargine100 U/ml once
daily at bedtime may offer glycaemic control benefits over
NPH insulin 100 U/ml once or twice daily, despite having
a comparable effect on HbA1c [14].
Conducting a single or double blinded trial was not
possible owing to the differences in dosing schedule be-
tween insulin glargine and NPH insulin. Assessment of
the outcomes, however, was based on objectively col-
lected data, namely, HbA1c evaluated by central labora-
tories blinded to the treatment as well as SMBG values.
Anotherone of the limitations of this study arose from
patients discontinuing treatment prematurely during the
treatment period, resulting in outcome data not being
reported for Week 24. Assessment of the primary and sec-
ondary endpoints for these patients was therefore conducted
using their last post-baseline on-treatment measurement for
the calculation of Week 24 (LOCF). Given that LOCF does
not take into consideration whether a patient’s condition
was improving or deteriorating at the time of dropout, the
analysis may have incorrectly increased, decreased or stabi-
lised patients’ glycaemic measures, thereby introducing
bias. The primary limitation of the present study,howe-
ver,was the reduction in enrolment targetsdue to diffi-
culties in the recruitment of patients. The small sample
size resulted in statistical comparisons that were under-
powered. Nonetheless, our results are broadly similar
to those of other studies that compared insulin glargine
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and NPH insulin. To the authors’ knowledge, this is the
first Phase III trial of insulin glargine in Chinese paedi-
atric patients with T1DM, and therefore the results of
the present study should be of value to the academic
community and prescribing physicians.
Conclusion
The results of this study provide evidence that in Chinese
paediatric patients with T1DM, insulin glargine provides
glycaemic control consistent with that observed in previ-
ous studies in Europe and the US, and may be associated
with a numerically lower incidence rate of hypoglycaemia
compared with NPH insulin. Insulin glargine was well
tolerated, with no new safety signals observed in this pre-
viously understudied Chinese T1DM population.
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